

Cefpodoxime Demonstrates Safety and Efficacy as Empirical Treatment for Adult Patients with Acute Upper Respiratory Tract Infections (URTIs)

Abdel Hamid O. *Egyptian Journal of Ear, Nose, Throat and Allied Sciences*. 2017; 18(2): 131-135.

- Cefpodoxime is a broad spectrum third generation cephalosporin active against Gram-negative and -positive bacteria. Empirical treatment with cefpodoxime is recommended for a wide range of community-acquired infections.
- Safety and efficacy of cefpodoxime (200 mg/day, for 5–10 days) for treatment of URTIs was evaluated in a prospective, observational, multicentre study in 1425 adults with acute maxillary sinusitis and tonsilopharyngitis.
- Significant reductions in URTI-related signs and symptoms were observed in subjects prescribed cefpodoxime for ~ 6 days. An 83.3% cure rate and a 16.2% improvement rate were noted for both acute maxillary sinusitis and tonsilopharyngitis patients. All AEs were mild to moderate in intensity; none were serious and all recovered.

High cure rates for acute maxillary sinusitis and acute tonsilopharyngitis, and a favorable safety and tolerability profile were noted following treatment with cefpodoxime.

Thus, cefpodoxime seems to be effective as empirical treatment in adults with acute URTIs.